Leukocytoclastic vasculitis after COVID-19 vaccine
Abstract
Several reports have described different types of vasculitis in temporal association with a variety of vaccines, and more recently with vaccines for COVID-19 disease. However, the scarcity of controlled studies and the methodological heterogeneity of the reports do not allow a clear conclusion about its causal relationship. We report the case of a male who developed leukocytoclastic vasculitis, confirmed by skin biopsy and without systemic involvement, after the second dose of Astra Zeneca's anti-COVID-19 vaccine.References
I. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res 2015;100:190-209. doi: 10.1016/j.phrs.2015.08.003.
II. Felicetti P, Trotta F, Bonetto C, et al. Spontaneous reports of vasculitis as an adverse event following immunization. A descriptive analysis across three international databases. Vaccine 2016;34(51):6634-6640. doi: 10.1016/j.vaccine.2015.09.027.
III. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005;38(3):235-245. doi: 10.1080/08916930500050277.
IV. Olivieri B, Betterle C, Zanoni G. Vaccinations and autoimmune diseases. Vaccines (Basel). 2021;9(8):815. doi: 10.3390/vaccines9080815.
V. Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review. Dermatologic Therapy 2022; 35(6): e15458. doi:10.1111/dth.15458.
VI. Sugita K, Kaneko S, Hisada R, et al. Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review. CEN Case Rep (2022). doi: 10.1007/s13730-022-00695-1.
VII. Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines 2021;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293.
VIII. Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272.
IX. Jara LJ, Vera-Lastra O, Mahroum N, Pineda C, Shoenfeld Y. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol 2022;41(5):1603-1609. doi: 10.1007/s10067-022-06149-4.
X. Izci-Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021;41(8):1523-1529. doi: 10.1007/s00296-021-04914-3.
XI. Mettler C, Jonville-Bera AP, Grandvuillemin A, Treluyer JM, Terrier B, Chouchana L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology (Oxford) 2022;61(2):865-867. doi: 10.1093/rheumatology/keab756.
XII. Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36(1):4-8. doi: 10.1016/j.jaut.2010.07.003.
XIII. Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). J Leukoc Biol 2022;111(3):725-734. doi: 1002/JLB.5COVR0621-320RR.
XIV. Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022;165(4):386-401. doi: 10.1111/imm.13443.
XV. Bonetto C, Trotta F, Felicetti P, et al. Vasculitis as an adverse event following immunization. Systematic literature review. Vaccine 2016;34(51):6641-6651. doi: 10.1016/j.vaccine.2015.09.026.
XVI. Hoffman GS, Calabrese LH. Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 2014;10(8):454-462. doi: 10.1038/nrrheum.2014.89.
Copyright (c) 2022 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
